Related Experiment Videos
Novel aromatase inhibitors.
A S Bhatnagar1, A Häusler, K Schieweck
1Research Department, CIBA-GEIGY Ltd., Basel, Switzerland.
The Journal of Steroid Biochemistry and Molecular Biology
|November 20, 1990
Summary
Two new non-steroidal aromatase inhibitors, CGS 16949A and CGS 18320B, demonstrate superior potency, selectivity, and efficacy compared to aminoglutethimide for breast cancer treatment.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Aminoglutethimide (AG) is an aromatase inhibitor used for breast cancer but lacks specificity and has moderate tolerability.
- Aromatase enzyme inhibition is a key strategy for reducing estrogen biosynthesis and treating hormone-dependent cancers.
Purpose of the Study:
- To introduce and evaluate two novel non-steroidal aromatase inhibitors, CGS 16949A and CGS 18320B.
- To compare the potency, selectivity, and efficacy of these new compounds against aminoglutethimide.
Main Methods:
- In vitro and in vivo assays to assess aromatase inhibition potency and selectivity.
- Administration to adult female rats to evaluate serum hormone responses and anti-tumor efficacy.
- Assessment of tumor regression and suppression of new tumor formation in DMBA-induced mammary tumor models.
Main Results:
- CGS 16949A and CGS 18320B are significantly more potent (400-1000x) and selective inhibitors of aromatase than AG.
- Both compounds induced hormonal changes similar to ovariectomy in rats.
- CGS 18320B demonstrated a longer duration of action than CGS 16949A.
- Significant regression of existing DMBA-induced mammary tumors and suppression of new tumor development were observed.
Conclusions:
- CGS 16949A and CGS 18320B represent substantial advancements over aminoglutethimide as aromatase inhibitors.
- These novel compounds offer improved potency, selectivity, and anti-tumor efficacy for potential breast cancer therapies.